CD36 (thrombospondin receptor) expression in childhood acute megakaryoblastic leukemia: In vitro drug sensitivity and outcome

Süeyya Savaşan, Steven Buck, Susana C. Raimondi, David L. Becton, Howard Weinstein, Myron Chang, Yaddanapudi Ravindranath

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Abstract

The outcome for children with acute megakaryoblastic leukemia (AMKL) remains poor, except for cases associated with Down syndrome (DS). This study compared immunophenotypic and drug sensitivity patterns of childhood AMKL cases with or without DS. All DS-AMKL cases showed high expression of CD36 and were very sensitive to cytarabine and daunorubicin in vitro. In children without DS, high expression of CD36 on AMKL blasts identified a sub-group with immunophenotypic and drug sensitivity patterns similar to that of DS AMKL. Among non-DS AMKL patients, CD36-high cases had a superior outcome compared with CD36-negative cases. CD36 expression in acute myeloid leukemia cases other than AMKL was not associated with increased in vitro drug sensitivity. CD36 expression in AMKL may be an indicator of megakaryoblast maturation and chemotherapy sensitivity.

Original languageEnglish
Pages (from-to)2076-2083
Number of pages8
JournalLeukemia and Lymphoma
Volume47
Issue number10
DOIs
StatePublished - Oct 2006

Keywords

  • CD36
  • Cytarabine
  • Daunorubicin
  • Down syndrome
  • Drug sensitivity
  • Immunophenotype
  • Megakaryoblastic leukemia

Fingerprint

Dive into the research topics of 'CD36 (thrombospondin receptor) expression in childhood acute megakaryoblastic leukemia: In vitro drug sensitivity and outcome'. Together they form a unique fingerprint.

Cite this